- PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
Sundar Jagannath, MD, is Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute. Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma — a relatively rare cancer of the bone marrow.
Prior to joining Mount Sinai, Dr. Jagannath served as chief of the multiple myeloma and transplant program at St. Vincent’s Hospital Comprehensive Cancer Center from 1998 until the hospital closed
in April 2010. The transplant program, with stored stem cells of more than 300 patients, and the myeloma program with ongoing clinical trials, have been integrated into The Tisch Cancer Institute.
Mount Sinai’s Multiple Myeloma Program provides clinical care to a large patient population, including the transfer of more than 800 patients who had been receiving care at St. Vincent’s.
Dr. Jagannath has published more than 180 peer-reviewed articles in top publications, including the New England Journal of Medicine, Blood, the Journal of Clinical Oncology and Cancer. He has presented more than 150 abstracts and authored nearly 30 book chapters.
American Board of Internal Medicine
MD, Maharaja Sayajirao University of Baroda, , Baroda Medical College
Residency, Internal Medicine
Bronx-Lebanon Hospital Center
Residency, Internal Medicine
Residency, Medical Oncology
MD Anderson Cancer Center (Univ of Texas)
Fellowship, Medical Oncology Fellowship
University of Texas - MD Anderson Cancer Center
An Expanded Access Program for Elotuzumab in Combination with Lenalidomide plus Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
The purpose of this expanded access program is to treat patients diagnosed with relapsed or refractory multiple myeloma with an investigational drug called elotuzumab. An expanded access program is a means by which the Food and Drug Administration (FDA) enables manufacturers t...
A Phase 2 Single Arm Study of Elotuzumab in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Multiple Myeloma Relapsed or Refractory to Prior Treatment with Lenalidomide
The purpose of this study is to determine the safety and effectiveness (how well the drug works) of the experimental new drug elotuzumab in combination with pomalidomide and low dose dexamethasone for the treatment of multiple myeloma patients who have relapsed after or are refra...
Oprozomib is an investigational new drug (a drug that has not received approval by the Food and Drug Administration [FDA]) that works by ...
A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (ricolinostat) in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma
You are being invited to join a clinical study, a type of research study for an experimental drug. "Experimental" means the drug has not been approved by any authority that regulates new drugs, such as the United States (US) Food and Drug Administration (FDA), and is not av...
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
The purpose of this study is to see how well the combination of pomalidomide, bortezomib and dexamethasone works compared to the combination of bortezomib an...
A Phase 2b, Open-Label, Single-Arm Study Of Selinexor (KPT-330) Plus Low-Dose Dexamethasone In Patients With Multiple Myeloma Refractory To Bortezomib, Lenalidomide, Carfilzomib And Pomalidomide
The purpose of this research study is to see if study drug selinexor (KPT-330) has any effects against your cancer. Selinexor (KPT-330) is considered investigational, which means it has not been approved by the U.S. Food and Drug Administration (FDA), Health Canada, the Eur...
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the U.S. Food and Drug Administration (FDA). They ha...
Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma
ABBV-838 (an investigational drug), which means that it has not yet been approved by the U.S. Food and Drug Administration (FDA). ABBV-838 is a protein called a monoclonal antibody that is coupled with a chemotherapeutic agent that may target and kill cancer cells, specific...
The purpose of this research study is to evaluate the dose limiting toxicities (side effects that are severe enough that you cannot take anymore drug at that dose) and the maximum...
A Phase I/II, Open-label, Multicenter Study of ACY-1215 administered Orally As Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
A Phase 1b Multicenter, Open-Label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) Either as Monotherapy or in Combination with Pomalidomide (POM) with or without Lowdose Dexamethasone (DEX) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM)
The purpose of this study is to test the safety of the combination of an experimental drug called durvalumab and pomalidomide at different dose levels, and to find out what effects, good or bad, the combination of these drugs has on you.
Pharmacyclics, Inc. is studying an experimental new drug called PCI-32765. An experimental drug is one that is being tested and is not approved by...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Jagannath during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Bristol-Myers Squibb
- Celgene Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.